US 12,344,869 B2
Nucleobase editors and uses thereof
David R. Liu, Cambridge, MA (US); Alexis Christine Komor, Cambridge, MA (US); Holly A. Rees, Cambridge, MA (US); and Yongjoo Kim, Cambridge, MA (US)
Assigned to President and Fellows of Harvard College, Cambridge, MA (US)
Filed by President and Fellows of Harvard College, Cambridge, MA (US)
Filed on Nov. 15, 2021, as Appl. No. 17/527,011.
Application 17/527,011 is a continuation of application No. 15/960,171, filed on Apr. 23, 2018, granted, now 11,214,780.
Application 15/960,171 is a continuation of application No. 15/331,852, filed on Oct. 22, 2016, granted, now 10,167,457.
Application 15/960,171 is a continuation of application No. PCT/US2016/058344, filed on Oct. 22, 2016.
Claims priority of provisional application 62/408,686, filed on Oct. 14, 2016.
Claims priority of provisional application 62/398,490, filed on Sep. 22, 2016.
Claims priority of provisional application 62/370,700, filed on Aug. 3, 2016.
Claims priority of provisional application 62/357,332, filed on Jun. 30, 2016.
Claims priority of provisional application 62/357,352, filed on Jun. 30, 2016.
Claims priority of provisional application 62/322,178, filed on Apr. 13, 2016.
Claims priority of provisional application 62/311,763, filed on Mar. 22, 2016.
Claims priority of provisional application 62/279,346, filed on Jan. 15, 2016.
Claims priority of provisional application 62/245,828, filed on Oct. 23, 2015.
Prior Publication US 2022/0220462 A1, Jul. 14, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/10 (2006.01); C07K 14/32 (2006.01); C12N 9/22 (2006.01); C12N 9/24 (2006.01); C12N 9/78 (2006.01); C12N 15/11 (2006.01); C12N 15/90 (2006.01)
CPC C12N 9/22 (2013.01) [C07K 14/32 (2013.01); C12N 9/2497 (2013.01); C12N 9/78 (2013.01); C12N 15/11 (2013.01); C12N 15/907 (2013.01); C12Y 305/04005 (2013.01); C07K 2319/00 (2013.01); C07K 2319/09 (2013.01); C07K 2319/80 (2013.01); C12N 2310/20 (2017.05); C12N 2800/80 (2013.01)] 34 Claims
 
1. A complex comprising:
(i) a Cas9 protein;
(ii) a cytidine deaminase;
(iii) a uracil glycosylase inhibitor (UGI) protein; and
(iv) a guide RNA (gRNA);
wherein the complex deaminates a cytidine in a target nucleic acid sequence.